Autonomix Highlights Renal Denervation Strategy and Vision for Illuminating the Nervous System at TCT 2026
Key Highlights
- ➤Autonomix (AMIX) targets a potential commercial offering by end of 2028.
- ➤Preclinical swine studies recorded electrical signals around three arteries before and after ablation.
- ➤Initial U.S. sensing clearance would exclude renal denervation guidance and treatment-verification claims.
- ➤Autonomix prioritizes standalone sensing as its initial regulatory and commercialization opportunity.
- ➤Platform development requires successful validation, sufficient financing and applicable regulatory authorizations.
Expert Statements
Brad Hauser, President and Chief Executive Officer of Autonomix Medical
“Our vision is to develop a ‘GPS’ for nerve-targeted procedures, combining sensitive electrical signal acquisition, mapping and real-time catheter positioning within blood vessels”
Brad Hauser, President and Chief Executive Officer of Autonomix Medical
“Renal denervation presents a compelling opportunity for this approach. Physicians are treating nerves involved in blood pressure regulation, yet they have limited access to direct measurements of neural activity during the procedure. We believe providing that additional information could become an important advancement in how these treatments are planned, delivered and assessed.”
Brad Hauser, President and Chief Executive Officer of Autonomix Medical
“Electrical mapping changed how physicians understand and treat abnormal heart rhythms”
Brad Hauser, President and Chief Executive Officer of Autonomix Medical
“We see the potential for sensing and mapping to bring a similar information advantage to renal denervation. By developing a platform that could work alongside different treatment technologies, we believe Autonomix has an opportunity to support innovation across the category and create potential collaborations with multiple therapy developers.”
Brad Hauser, President and Chief Executive Officer of Autonomix Medical
“Our focus is on building the sensing foundation and translating it into useful information for physicians”
Brad Hauser, President and Chief Executive Officer of Autonomix Medical
“TCT provided an opportunity to share our early research with the cardiovascular community and discuss the potential role of this technology in the evolving renal denervation field.”
Microchip-enabled sensing platform aims to combine signal acquisition, mapping and real-time catheter positioning to support future nerve-targeted procedures
THE WOODLANDS, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today highlighted its presentation at the 2026 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Conference and its strategic focus on advancing its proprietary sensing platform for potential applications in renal denervation.
Get started
Create a free account to read the full story.